Trastuzumab Resistance: Bringing Tailored Therapy to the Clinic
October 1st 2008As Calabrich and colleagues illustrate in their comprehensive review in this issue of ONCOLOGY, there is a seemingly endless array of mechanisms by which the HER2-positive breast cancer cell can escape the control of trastuzumab (Herceptin).